360° Coverage : Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at...

1 Updates

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is...

Filed under: news

YouTube Videos

 
 
 

1 year ago

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

Study Design

This is a 48-week, double-blind, multiple dose, parallel group trial to compare the safety, efficacy, immunogenicity and tolerability of an experimental drug to Rituxan and MabThera in patients with moderately to severely active RA. Patients will be enrolled across 250 clinical sites, in 26 countries.

Part I (48-week duration) will include 150 patients, which is considered sufficient for pharmacokinetics (PK) testing. Part II consists of a 48-week comparative safety/efficacy analyses with an additional 150 patients.

Background & Rationale

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by synovial inflammation in the joints and consequently, progressive joint destruction. Depending on the severity of the disease, systemic manifestations may occur including lung disease, rheumatoid nodules and cardiovascular system effects. Without effective RA treatment, this disease may lead to severe functional disabilities, and therefore a considerable reduction in quality of life for the patient. The prevalence of RA varies with factors such as gender, race and smoking status and is approximately 0.5-1%.

B lymphocytes (B cells) are thought to play a crucial role in the pathogenesis of RA. They are also the primary source of rheumatoid factors (RFs) and anti-cyclic citrullinated peptide (anti-CCP) antibodies which contribute to the formation of immune complexes and complement activation in inflamed joints. Thus, B cell targeted therapy could play an important role in RA through a reduction in the B cell count as well as a reduction in B cell-mediated downstream effects on other cell types involved in the inflammatory response.

Primary Objectives

The primary objectives of this trial are:

To show PK similarity of this new drug to MabThera and Rituxan and of Rituxan to MabThera (three-way PK similarity).
To establish statistical equivalence of efficacy of this new drug and Rituxan/MabThera, in patients with moderately to severely active RA

Inclusion Criteria

Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months

Patients must have had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor.

Positive for RF and/or anti-CCP antibodies.

Current treatment for RA on an outpatient basis:

-- Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1.

-- Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).

-- Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks prior to Day 1.

-- Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout.

-- If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.

-- Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 or throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion
as this is part of the trial procedures.

-- Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.

-- Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day.

*Achieve Clinical Research conducts Phase II-IV Clinical Trials in Alabama. For more information about participating in an RA Clinical Study, please visit our website or contact us directly at (205) 380-6434.

Contact Information:
Achieve Clinical Research
Lashondra Cade
(205) 380-6434 320
Contact via Email
www.achieveclinical.com

Read the full story here: http://www.pr.com/press-release/520216

Press Release Distributed by PR.com

Source: PR.com

 

Don't miss ...

 

blog comments powered by Disqus

Latest stories

Germany unveils special jet to transport Ebola patients
Berlin, Nov 28 (IANS) The German government unveiled Thursday at Berlin's Tegel Airport a special medical evacuation plane, which is designed to transport patients infected with Ebola.
 
 
OPEC decides against oil production cut despite price slump
Viena, Nov 28 (IANS) The ministers of the Organization of Petroleum Exporting Countries(OPEC) decided here Thursday to maintain its output level despite crude oil price fell to a four-year low level.
 
 
18th Saarc Summit concludes with one pact, several understandings
Kathmandu, Nov 27 (IANS) The 18th South Asian Association for Regional Cooperation (Saarc) Summit concluded in Kathmandu Thursday with the adoption of a 36-point Kathmandu Declaration.
 
 
British supermarkets sold contaminated chicken
London, Nov 27 (IANS) Eight of the every 10 fresh chickens bought from British supermarkets this summer were contaminated with the potentially lethal food-poisoning bug campylobacter, the food watchdog has said.
 
 
 

Latest from the Network

OPEC decides against oil production cut despite price slump
Viena, Nov 28 (IANS) The ministers of the Organization of Petroleum Exporting Countries(OPEC) decided here Thursday to maintain its output level despite crude oil price fell to a four-year low level. The decision to...
Read more on Business Balla
 
12 killed in bus accident in Egypt
Cairo, Nov 28 (IANS) At least 12 people were killed and three others injured Thursday as a passenger bus overturned into a canal in Egypt's Beni Sweif province, around 120 km south of the capital Cairo, media reported...
Read more on Politics Balla
 
Explosions, gun fire rock Kabul diplomatic enclave
Kabul, Nov 27 (IANS) Two explosions followed by gunfire rocked the diplomatic enclave here Thursday night, a security officer said. The area of the blast is close to the Tajikistan embassy. The incident occurred in...
Read more on Politics Balla
 
Saarc leaders' wives ladies go sight-seeing at Bhaktapur
Kathmandu, Nov 27 (IANS) While the Saarc leaders conferred on regional matters at the tourist resort of Dhulikhel, their wives drove to the World Heritage Site of Bhaktapur to enjoy the sights of the ancient city. The...
Read more on Politics Balla
 
Maria Shriver 'disgusted' by Miley Cyrus's party
Patrick Schwarzenegger's mother was ''disgusted'' by Miley Cyrus's birthday celebrations. Maria Shriver - who, along with Arnold Schwarzenegger, are the parents of the 21-year-old actor - is reportedly ''very worried''...
Read more on Celebrity Balla
 
Kim Kardashian and Kanye West planning nude photoshoot together?
Kim Kardashian West and Kanye West want to do a nude photoshoot together. The couple are reportedly keen to pose naked alongside each other, after the 34-year-old 'Keeping Up With The Kardashians' star recently stripped...
Read more on Celebrity Balla